AstraZeneca licenses Ionis' NASH drug for $30M as momentum builds in the field
Just months after a deal with identical payouts, Ionis today announced it’s licensing yet another one of its drugs to AstraZeneca. The pharma giant is paying a $30 million license fee to gain access to Ionis’ NASH drug, with $300 million available in milestones should the program have boundless success.
The program, called IONIS-AZ6-2.5LRx, is designed to inhibit an undisclosed target to treat patients with NASH, a space that continues to bubble with activity, although no approved treatments have hit the market. Last week, San Mateo-based Terns said it would snatch up three NASH programs from Eli Lilly, and in March Alnylam and Regeneron teamed up to tackle a promising target for sever liver diseases.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
